The global urinary tract infections market is forecasted at USD 10.07 billion in 2020 and is estimated to be growing at a CAGR of 2.14%, to reach USD 11.19 billion by 2025.
Urinary Tract Infection is an infection that affects parts of the urinary tract. When it affects the lower urinary tract, it is called a bladder infection or cystitis, and when it affects the upper urinary tract, it is called kidney infection or pyelonephritis. A UTI can happen anywhere in your urinary tract. Your urinary tract is made up of your kidneys, ureters, bladder, and urethra. Most UTIs only involve the urethra and bladder in the lower tract. However, UTIs can involve the ureters and kidneys in the upper tract. Although upper tract UTIs are rarer than lower tract UTIs, they’re also usually more severe. UTI symptoms are burning, increased frequency of urination, bloody urine, pelvic pain in women, rectal pain in men, urine that looks like cola or tea. Today Urinary Tract Infections are most common in women.
The most common cause of infection is E coli, though other fungi or bacteria may rarely be the cause. Risk factors include female anatomy, diabetes, obesity, sexual intercourse, and family history. Although sexual intercourse is a risk factor, urinary tract infections are not categorized as sexually transmitted infections. If kidney infection occurs, it usually follows a bladder infection and results from infection, which is blood-borne in nature. Diagnosis in young, healthy women can be based alone on symptoms. In those with vague symptoms, diagnosis is difficult since bacteria may be present without an infection. In complicated cases or when conventional treatments fail, a urine culture may be useful.
The driving factors of the global urinary tract infections market are the sudden rise in the prevalence rate and the disease's diagnosis. This has started the opportunities for major players to allocate their resources towards combination therapy research and development. This will surely result in the growth of market size during the forecast period. With the launch of new drugs for multiple indications under urinary tract infections and label expansion for already existing drugs, the market is expected to boost further. The generic, low-cost competition for some of the drugs is fierce and is forecasted to get more competitive and thus can contribute to offsetting the figures for the current market size.
Complicated regulatory monitoring hampers the urinary tract infections market. Several companies have prevented or reduced the research and development activities in advancing antibiotics as they have a low return on investments. The investments required for the research and development activities for new drugs and antibiotics are comparatively low. This factor is to limit the market growth. Lack of awareness regarding the frequent urinary tract infections in the developed and underdeveloped countries is restraining the market growth. The clinical trials for preparing antibacterial drugs are challenging and require an instructive, ethical, and scientific approach. The mentioned-above factor obstructs the market growth.
Impact of COVID-19 on the global urinary tract infections market:
The novel coronavirus (COVID 19), which turned into a worldwide pandemic, infected millions of people and caused thousands to death. The common comorbidity in COVID 19 positive patients is diabetes, chronic lung disease, and hypertension. People with 60 years and above or suffering from health conditions like diabetes, heart or lung disease, which affects their immune system, are more likely to suffer from COVID 19. Not only efficient of causing respiratory illness, but the COVID 19 may also damage the organ systems of the human body along with urogenital systems. The COVID 19 sensitivity may result in bladder dysfunction.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type of Medication, Type of indication and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This research report on the global urinary tract infections market has been segmented and sub-segmented based on the type of medication, type of indication, and region.
Urinary Tract Infections Market – By Type of Medication:
Based on the type of medication, the quinolones segment is expected to lead the global urinary tract infection market and held 37.7% of the share in 2019. Many physicians suggest the patients about the intake of quinolones get rid of their infection quickly.
The penicillin and combinations segments are predicted to grow at the highest CAGR growth rate during the forecast period.
Urinary Tract Infections Market – By Type of Indication:
Based on the type of indication, the complicated UTIs segment dominates the UTI and accounts to hold most of the market share. The segment growth depends on mushrooming drug-resistant bacteria and enormous usage of antibiotics. Many medical professionals prescribe quinolones for treating complicated urinary tract infections among patients—the regularity of complicated UTIs to escalate throughout the forecasting period. According to the Queensland Pediatric Factsheet 2019, around 1 in 10girls and 1 in 50 boys suffer from urinary tract infections by seven years of age.
Urinary Tract Infections Market – By Region:
Regionally, the Asia Pacific region has the largest market for urinary tract infections globally by share and is also the fastest-growing region, owing to factors such as rising rate of diagnostics, gradual adoption of improved technologies, emerging health care infrastructures, and increased disposable income. Europe and North America have the second and third largest market shares respectively.
KEY PARTICIPANTS IN THE MARKET:
Some of the noteworthy companies leading the global urinary tract infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd.
RECENT HAPPENINGS IN THIS MARKET:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Medication
5.1.1 Penicillin & Combinations
5.1.1.1 Amoxicillin
5.1.1.2 Amoxicillin-Clavulanate Potassium combination
5.1.2 Quinolones
5.1.2.1 Ciprofloxacin
5.1.2.2 Levofloxacin
5.1.2.3 Norfloxacin
5.1.2.4 Nalidixic Acid
5.1.3 Aminoglycoside-Antibodies
5.1.3.1 Gentamicin
5.1.3.2 Amikacin
5.1.4 Cephalosporin
5.1.4.1 Ceftriaxone
5.1.4.2 Cefixime
5.1.4.3 Cefuroxime
5.1.4.4 Cephalexin
5.1.5 Sulphonamides
5.1.5.1 Sulfamethoxazole
5.1.5.2 Trimethoprim combination
5.1.6 Azoles & Amphotericin B
5.1.7 Tetracycline
5.1.7.1 Doxycycline
5.1.7.2 Nitrofurans
5.1.8 Nitrofurans
5.1.9 Y-o-Y Growth Analysis, By Type of Medication
5.1.10 Market Attractiveness Analysis, By Type of Medication
5.1.11 Market Share Analysis, By Type of Medication
5.2 Type of Indication
5.2.1 Uncomplicated UTI
5.2.2 Complicated UTI
5.2.3 Recurring Complicated UTI
5.2.4 Neurogenic Bladder Infection
5.2.5 Y-o-Y Growth Analysis, By Type of Indication
5.2.6 Market Attractiveness Analysis, By Type of Indication
5.2.7 Market Share Analysis, By Type of Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Type of Medication
6.1.3.2 By Type of Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Type of Medication
6.1.4.2 By Type of Indication
6.1.5 Market Share Analysis
6.1.5.1 By Type of Medication
6.1.5.2 By Type of Indication
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AstraZeneca plc
8.3 Johnson & Johnson
8.4 Novartis International AG.
8.5 F. Hoffmann La Roche Ltd.
8.6 Teva Pharmaceutical Industries Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Cipla Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
